Shares of Pulmonx Co. (NASDAQ:LUNG – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ...

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced ...

Pulmonx Corporation (LUNG) closed the last trading session at $6.20, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

On Wednesday, Citi issued a downgrade for Pulmonx Corp . (NASDAQ:LUNG) from a "Buy" to a "Neutral" rating, accompanied by a significant reduction in the price target to $7.50 from the previous $17.00.

Pulmonx Corporation (LUNG) has disclosed a new risk, in the Share Price & Shareholder Rights category. Pulmonx Corporation ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...